✦ LIBER ✦

First-line endocrine therapy in postmenopausal (PM) patients (pts) with advanced breast cancer (ABC) and visceral metastases (mets): Anastrozole (AN) versus tamoxifen (TAM)

✍ Scribed by I. Vergote; B. Thürlimann

Book ID: 117658552
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 184 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)81189-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of tamoxifen (TAM) following An

Efficacy of tamoxifen (TAM) following Anastrozole (AN) as first-line treatment for Advanced Breast Cancer (ABC) in Postmenopausal (PM) Patients (PTS)

✍ B. Thürlimann; J.F.R. Robertson; J. Bonneterre; A. Buzdar; J.M. Nabholtz 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Phase III trial of Anastrozole (AN) vs T

Phase III trial of Anastrozole (AN) vs Tamoxifen (TAM) in Postmenopausal (PM) Patients (PTS) with hormone-dependent Advanced Breast Cancer (ABC)

✍ A. Milla-Santos; L. Milla; L. Rallo 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 165 KB

Exemestane versus anastrozole as front-l

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

✍ Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Ant 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

Anastrozole (‘Arimidex’) versus tamoxife

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

✍ Beat Thürlimann; Dagmar Hess; Dieter Köberle; Isabella Senn; Pierluigi Ballabeni 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 348 KB